Tags

Type your tag names separated by a space and hit enter

Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.

Abstract

High-risk resectable melanoma poses therapeutic challenges as this subgroup remains most vulnerable for disease recurrence. Immunotherapy has established its efficacy in cases of advanced melanoma, and now is actively being investigated in the multimodal management of resectable disease. Daromun, an intralesional immunocytokine, has emerged as a unique immunotherapy in its ability to preferentially target tumor cells, resulting in direct destruction, while generating a bystander effect that leads to a distant treatment effect. On the basis of its mechanism of action, there is growing interest in delivering immune-based therapies in a neoadjuvant setting. In this review, the neo-DREAM study, a Phase III trial comparing the safety and efficacy of neoadjuvant Daromun for resectable stage IIIB/C melanoma will be described. Clinical Trial Registration Number: NCT03567889.

Authors+Show Affiliations

Departments of Cutaneous Oncology & Sarcoma, Moffitt Cancer Center, Tampa, FL 33612, USA. Department of Surgery, University of South Florida School of Medicine, Tampa FL, USA.Departments of Cutaneous Oncology & Sarcoma, Moffitt Cancer Center, Tampa, FL 33612, USA. Department of Surgery, University of South Florida School of Medicine, Tampa FL, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31538818

Citation

Miura, John T., and Jonathan S. Zager. "Neo-DREAM Study Investigating Daromun for the Treatment of Clinical Stage IIIB/C Melanoma." Future Oncology (London, England), 2019.
Miura JT, Zager JS. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. Future Oncol. 2019.
Miura, J. T., & Zager, J. S. (2019). Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. Future Oncology (London, England), doi:10.2217/fon-2019-0433.
Miura JT, Zager JS. Neo-DREAM Study Investigating Daromun for the Treatment of Clinical Stage IIIB/C Melanoma. Future Oncol. 2019 Sep 20; PubMed PMID: 31538818.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma. AU - Miura,John T, AU - Zager,Jonathan S, Y1 - 2019/09/20/ PY - 2019/9/21/entrez KW - Daromun KW - IL-2 KW - L19 KW - TNF KW - adjuvant KW - immunotherapy KW - intralesional therapy KW - melanoma KW - neoadjuvant KW - surgery JF - Future oncology (London, England) JO - Future Oncol N2 - High-risk resectable melanoma poses therapeutic challenges as this subgroup remains most vulnerable for disease recurrence. Immunotherapy has established its efficacy in cases of advanced melanoma, and now is actively being investigated in the multimodal management of resectable disease. Daromun, an intralesional immunocytokine, has emerged as a unique immunotherapy in its ability to preferentially target tumor cells, resulting in direct destruction, while generating a bystander effect that leads to a distant treatment effect. On the basis of its mechanism of action, there is growing interest in delivering immune-based therapies in a neoadjuvant setting. In this review, the neo-DREAM study, a Phase III trial comparing the safety and efficacy of neoadjuvant Daromun for resectable stage IIIB/C melanoma will be described. Clinical Trial Registration Number: NCT03567889. SN - 1744-8301 UR - https://www.unboundmedicine.com/medline/citation/31538818/Neo-DREAM_study_investigating_Daromun_for_the_treatment_of_clinical_stage_IIIB/C_melanoma L2 - http://www.futuremedicine.com/doi/full/10.2217/fon-2019-0433?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -